Isomorphic Labs Raises $5 Billion for AI Drug Discovery

Abstract illustration of AI-driven drug discovery, DNA helix merging into molecular structures
Illustration: AI-driven drug discovery concept (AI-generated, no real photo of Isomorphic Labs' operations was available).

Last updated: November 18, 2026, 01:20 IST.

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The company says the funding will push its AI-designed drug candidates toward human clinical trials, following what it called “positive preclinical results” in oncology and immunology.

How big the round is, and who backed it

The $5 billion Series C was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor alongside existing backers, according to TechCrunch‘s reporting. Isomorphic Labs has not disclosed its resulting valuation, though earlier Bloomberg reporting this month described the company as seeking funding at roughly $50 billion.

The new round follows a $2.1 billion Series B closed in May 2026, which was also led by Thrive Capital. Isomorphic Labs has now raised more than $7 billion in less than a year, a pace that reflects how much investor money is chasing AI-driven drug discovery specifically, rather than AI more broadly.

What the funding is actually for

Isomorphic Labs says it will use the new capital to continue developing its AI drug-design engine and to expand into additional types of medicine beyond its current focus areas. The company pointed to “positive preclinical results” in oncology and immunology as the basis for pushing some of its AI-designed candidates toward human clinical trials, the stage where a drug is tested in people rather than in lab models.

Clinical trials are also where AI drug discovery companies have historically struggled to prove their underlying promise: identifying a promising molecule faster with AI is one thing, but getting that molecule through the three-phase human trial process that regulators require is a separate, multi-year test that a faster starting point does not automatically shorten.

Its roots in Google DeepMind

Isomorphic Labs was spun out of Google DeepMind, the Alphabet-owned AI lab behind AlphaFold, the protein-structure prediction system that won its creators a Nobel Prize. Isomorphic Labs applies similar AI modeling techniques to drug design specifically, aiming to predict how candidate molecules will behave in the body before they are physically synthesized and tested.

Leadership and a slipping clinical-trial target

Isomorphic Labs is led by Sir Demis Hassabis as founder and chief executive, with president Max Jaderberg running day-to-day operations, according to the company’s own leadership statements reported by Fortune. Hassabis, who also holds senior roles at Google DeepMind and won a Nobel Prize for AlphaFold’s protein-structure predictions, had earlier targeted getting an AI-designed drug into human clinical trials by the end of 2025. That target has already slipped once, to the end of 2026, a reminder that AI can speed up the discovery phase of drug development without necessarily speeding up the regulatory and trial phases that follow it.

What to watch next

The real test of this funding round will not be visible for years: whether any of Isomorphic Labs’ AI-designed candidates actually clear human clinical trials and reach approval, the point at which AI drug discovery’s commercial promise gets tested against regulators and patients rather than against lab benchmarks. The company’s own revised end-of-2026 clinical trial target is the nearest milestone to watch.

Source: TechCrunch, Isomorphic Labs.